Trial in progress: a phase 3, multi-regional, open-label, randomized study of tirabrutinib vs rituximab and temozolomide in participants with relapsed/refractory primary central nervous system lymphoma
A phase 1 study of DCC-2036, a novel oral inhibitor of BCR-ABL kinase, in adult subjects with Philadelphia chromosome positive (Ph+) leukemias including subjects with T315I mutation.
